CheckMate-816

一行要約

切除可能 stage IB-IIIA NSCLC への術前 Nivolumab + 化療 vs 化療単独の phase III。pCR 24.0% vs 2.2% (OR 13.94)、EFS HR 0.63 で 周術期 IO+chemo standard を確立、neoadjuvant IO paradigm の global landmark。

試験デザイン

• 対象: Stage IB-IIIA (8th edition)、切除可能、未治療、EGFR/ALK 陰性、N=358
• 介入群 (n=179) : 術前 Nivolumab 360mg + Platinum-doublet × 3 cycles → 手術
• 対照群 (n=179) : 術前 Platinum-doublet × 3 cycles → 手術
• 術後 adjuvant chemotherapy / radiotherapy は治験医師判断 (任意)
• Co-primary: pCR、EFS

主要結果

• pCR (primary) : 24.0% vs 2.2% (OR 13.94, P<0.0001)
• MPR (major pathological response, ≤10% viable) : 36.9% vs 8.9%
• EFS (primary) : HR 0.63 (97.38% CI 0.43–0.91), median 31.6 vs 20.8 mo
• R0 resection: 83% vs 78%
• OS (4-yr update Spicer et al. Lancet 2024) : HR 0.71、4-yr OS 71% vs 58%
• AE: Grade 3-4 33.5% vs 36.9% (IO 併用で増加なし)、surgery delay rare

臨床的意義

• Stage IB-IIIA NSCLC neoadjuvant IO+chemo を新標準化 (FDA 2022 承認、global guideline 改訂)
• pCR 改善が EFS / OS に変換される paradigm
• Surgery feasibility は化療単独と同等 — neoadjuvant IO の安全性確認
• 後続: KEYNOTE-671 (perioperative Pembro) / AEGEAN (Durva) / NEOTORCH / RATIONALE 315 が周術期領域を拡張

Open Questions

• Neoadjuvant only vs perioperative (neoadj+adj) IO: AEGEAN / KEYNOTE-671 / NEOTORCH の比較で adjuvant IO 部分の incremental benefit
• pCR achievers での adjuvant IO 必要性: de-escalation の妥当性
• PD-L1 cutoff での効果: TPS <1% で IO+chemo 効果限定の可能性
• EGFR/ALK+ resectable NSCLC: 試験除外群、ADAURA / ALINA との echo
• Stage IB (small tumor) への適応拡大: 8th edition では IA3 / IB が小腫瘍

重要論文 Top 10

1. ★★★★★ Forde et al. NEnglJMed 2022 — CheckMate-816 primary publication
2. ★★★★★ Forde et al. NEnglJMed 2018 — Phase II Nivolumab neoadjuvant pioneer
3. NEJM-2024-Spicer-Surgical outcomes following neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer — Surgery outcomes detail
4. ★★★★ Wakelee et al. NEnglJMed 2023 — KEYNOTE-671 — perioperative IO+chemo
5. ★★★★ Heymach et al. NEnglJMed 2023 — AEGEAN — perioperative durvalumab

関連エンティティ

• 薬剤クラス: PD-1-inhibitor (Nivolumab)
• biomarker: PD-L1 / TP53
• 関連試験: KEYNOTE-189 / KEYNOTE-024 / KEYNOTE-671 / AEGEAN
• ドメイン: lung-cancer-treatment

関連論文

Basic-Immunotherapy

• Sharma et al. Cell 2023 — Immune checkpoint therapy-current perspectives and future directions

Basic-Liquid-biopsy

• Cai et al. JImmunotherCancer 2026 — Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer integrated

Basic-Others

• Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer
• Rozeman et al. NatMed 2021 — Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Clinical-Epidemiology

• Potter et al. AnnThoracSurg 2023 — Recurrence after complete resection for non-small cell lung cancer in the national lung screening trial

Clinical-NSCLC-Driver negative

• Chaft et al. AnnThoracSurg 2017 — Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors
• Tanaka et al. AnnThoracSurg 2018 — Induction chemoradiotherapy (50 gy), followed by resection, for stage IIIA-N2 non-small cell lung cancer
• Spicer et al. AnnThoracSurg 2019 — Multimodality therapy for N2 non-small cell lung cancer an evolving paradigm
• Katakami et al. Cancer 2012 — A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients
• Rocha et al. ClinCancerRes 2022 — Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy, and chemoimmunotherapy in
• Rossi et al. ESMOOpen 2025 — Immunotherapy for resectable NSCLC neoadjuvantperioperative followed by surgery over surgery followed by adjuvant
• Speicher et al. EurJCardiothoracSurg 2015 — Outcomes after treatment of 17,378 patients with locally advanced (T3N0-2) non-small-cell lung cancer
• Chaft et al. JAMA 2026 — Adjuvant nivolumab vs observation in resected Non-Small cell lung cancer
• Provencio et al. JClinOncol 2022 — Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA
• NSCLC et al. Lancet 2014 — Preoperative chemotherapy for NSCLC A systematic review and meta-analysis of individual participant data
• Pless et al. Lancet 2015 — Induction chemoradiation in stage IIIAN2 non-small-cell lung cancer a phase 3 randomised trial
• Spicer et al. Lancet 2024 — Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy
• Eichhorn et al. LungCancer 2021 — Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer first
• Forde et al. NEnglJMed 2018 — Neoadjuvant PD-1 blockade in resectable lung cancer
• Forde et al. NEnglJMed 2022 — Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
• Heymach et al. NEnglJMed 2023 — Perioperative durvalumab for resectable non-small-cell lung cancer
• Wakelee et al. NEnglJMed 2023 — Perioperative pembrolizumab for early-stage non-small-cell lung cancer
• Provencio et al. NatCancer 2026 — Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC phase 3
• Wang et al. NatMed 2021 — Toward personalized treatment approaches for non-small-cell lung cancer

Clinical-NSCLC-EGFR

• Zhao et al. CancerTreatRev 2026 — Perioperative strategies for resectable EGFR-mutant NSCLC evidence hierarchy and clinical decision-making

Clinical-Others

• Zhu et al. IntJRadiatOncolBiolPhys 2026 — Low-dose SBRT-based radiotherapy followed by pembrolizumab and chemotherapy for potentially resectable NSCLC A phase ib

Clinical-irAE

• Govindan et al. JImmunotherCancer 2022 — Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung